Covation Biomaterials announced launch of BioPTMEG at Chinaplas

Covation Biomaterials (Newark, DE, USA), a biomaterials company with advanced technology in the biobased materials industry, proudly announces its newest innovation, CovationBio bioPTMEG, the advanced, sustainable polytetramethylene ether glycol (PTMEG), delivering high performance with significantly lower environmental impact.

BioPTMEG is a biobased alternative to petroleum-based PTMEG, helping customers reduce their reliance on non-renewable materials and maintain the durability and resilience expected in high performance applications such as spandex, polyurethanes and thermoplastic elastomers.

A few of the superior sustainability benefits offered by CovationBio^® bioPTMEG include:
• a substantial reduction of greenhouse gas emissions compared to fossil-based incumbents;
• a product that is 100 % biobased and obtained from annually renewable resources;
• the use of feedstock such as corncobs which do not compete with primary food sources;
• a reduced reliance on non-renewable fossil fuel use.
• Drop-in performance to allow downstream to switch to biobased raw material without major process change

Feifeng You, Chairman of CovationBio, stated: “As a force of nature, CovationBio’s vision is to build a sustainable, decarbonized materials industry. To this end, we’re proud to launch CovationBio bioPTMEG. It uses carbon absorbed by plants from the atmosphere for material creation, improving the quality of life. We’re scaling up production to cut carbon footprints. This is our responsibility to future generations. Through continuous innovation and cooperation, we aim to build a sustainable and regenerative materials industry. We invite all stakeholders to join us in creating a greener, cleaner, and more prosperous world. This drop-in replacement can be seamlessly integrated into existing manufacturing processes and does norequire extensive, or even any, product development.”

The construction of a plant in Jiangsu Province, Qidong is expected to be mechanically complete toward the end of 2025. Commercial production should begin in the first quarter of 2026. AT

covationbio.com